Clinical trials
Phase 4 Mouth Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
9 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 3 |
| Recruiting | 2 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ain Shams University | 1 |
| Fox Chase Cancer Center | 1 |
| Lisa Sanderson Cox, PhD | 1 |
| M.D. Anderson Cancer Center | 1 |
| McMaster University | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| OHSU Knight Cancer Institute | 1 |
| Oxford University Hospitals NHS Trust | 1 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mouth Neoplasms | 9 |
| Head and Neck Neoplasms | 4 |
| Hypopharyngeal Neoplasms | 4 |
| Oropharyngeal Neoplasms | 4 |
| Laryngeal Neoplasms | 3 |
| Nasopharyngeal Neoplasms | 3 |
| Carcinoma, Hepatocellular | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Carcinoma, Renal Cell | 2 |
| Esophageal Neoplasms | 2 |
Trials
Showing 76 to 9 of 9. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.